Analysis of the disease burden of non-Hodgkin lymphoma in China from 1990 to 2019_Chinese Journal of Evidence-Based Medicine

Authors：

XIAO Hui , WU Fan , AN Furun ,  ZHAI Zhimin

Department of Hematology, the Second Affiliated Hospital of Anhui Medical University, Hefei 230601, P. R. China;

Corresponding author：

ZHAI Zhimin, Email: zzzm889@163.com

Keywords：

Non-Hodgkin's lymphoma; Disease burden; Joinpoint regression; Disability-adjusted life years

DOI：

10.7507/1672-2531.202303171

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To analyze the disease burden and development trend of non-Hodgkin lymphoma (NHL) in China from 1990 to 2019. Methods The changes of incidence, mortality, disability-adjusted life years (DALY) and their corresponding age-normalization rates for NHL were analyzed by using the 2019 Global Burden of Disease Database. Regression analysis was performed by Joinpoint software to calculate annual percentage change (APC) and average annual percentage change (AAPC) of standardized morbidity, standardized mortality, standardized DALY rate to reflect the change trend of disease burden. And the results were compared with global data. Results From 1990 to 2019, the disease burden of NHL in China showed an overall increasing trend. Compared with 2019, the standard incidence rate, standard mortality rate and standard DALY rate of NHL in China increased by 144.72%, 27.17% and 15.61%, respectively. The annual rates of change were 3.12%, 0.80% and 0.51%, respectively. There were gender and age differences in disease burden. The burden of disease increased with age, and the burden of disease was higher in males than in females. Conclusion The disease burden of NHL in China shows an increasing trend from 1990 to 2019. With the development of diagnosis and treatment options, the disease burden has decreased in recent years, but it is still higher than the global level. There is still a need to strengthen research on its pathogenesis and treatment options, and to actively intervene in high-risk groups to reduce the disease burden of NHL.

Citation： XIAO Hui, WU Fan, AN Furun, ZHAI Zhimin. Analysis of the disease burden of non-Hodgkin lymphoma in China from 1990 to 2019. Chinese Journal of Evidence-Based Medicine, 2023, 23(8): 880-886. doi: 10.7507/1672-2531.202303171 Copy

1.	Armitage JO, Gascoyne RD, Lunning MA, et al. Non-Hodgkin lymphoma. Lancet, 2017, 390(10091): 298-310.
2.	GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990—2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, 2020, 396(10258): 1204-1222.
3.	Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl), 2021, 134(7): 783-791.
4.	Liu W, Liu J, Song Y, et al. Burden of lymphoma in China, 2006-2016: an analysis of the Global Burden of Disease Study 2016. J Hematol Oncol, 2019, 12(1): 115.
5.	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
6.	GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990—2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, 2020, 396(10258): 1223-1249.
7.	屈彦, 王天一, 杨津, 等. GBD数据库的数据提取方法与流程. 中国循证心血管医学杂志, 2019, 11(9): 1043-1046.
8.	李茜瑶, 周莹, 黄辉, 等. 疾病负担研究进展. 中国公共卫生, 2018, 34(5): 777-780.
9.	李辉章, 杜灵彬. Joinpoint回归模型在肿瘤流行病学时间趋势分析中的应用. 中华预防医学杂志, 2020, 54(8): 908-912.
10.	Chen HS, Zeichner S, Anderson RN, et al. The Joinpoint-jump and Joinpoint-comparability ratio model for trend analysis with applications to coding changes in health statistics. J Off Stat, 2020, 36(1): 49-62.
11.	胡成如, 王丽, 孙茜, 等. 体重指数与恶性淋巴瘤关系病例对照研究的Meta分析. 中国循证医学杂志, 2012, 12(1): 55-60.
12.	't Mannetje A, De Roos AJ, Boffetta P, et al. Occupation and risk of non-Hodgkin lymphoma and its subtypes: a pooled analysis from the InterLymph Consortium. Environ Health Perspect, 2016, 124(4): 396-405.
13.	Morton LM, Slager SL, Cerhan JR, et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr, 2014, 2014(48): 130-144.
14.	杜鹏, 李龙. 新时代中国人口老龄化长期趋势预测. 中国人民大学学报, 2021, 35(1): 96-109.
15.	修冰, 刘辉, 李玉兰, 等. CAR-T治疗B细胞淋巴瘤研究新进展. 临床内科杂志, 2022, 39(9): 586-589.
16.	Bock AM, Nowakowski GS, Wang Y. Bispecific antibodies for non-Hodgkin lymphoma treatment. Curr Treat Options Oncol, 2022, 23(2): 155-170.
17.	Yip W, Fu H, Chen AT, et al. 10 years of health-care reform in China: progress and gaps in Universal Health Coverage. Lancet, 2019, 394(10204): 1192-1204.
18.	Yu H. Universal health insurance coverage for 1.3 billion people:what accounts for China's success? Health Policy, 2015, 119(9): 1145-1152.
19.	Liu W, Liu J, Song Y, et al. Burden of lymphoma in China, 1990—2019: an analysis of the global burden of diseases, injuries, and risk factors study 2019. Aging (Albany NY), 2022, 14(7): 3175-3190.
20.	Cai W, Zeng Q, Zhang X, et al. Trends analysis of non-Hodgkin lymphoma at the national, regional, and global level, 1990—2019: results from the Global Burden of Disease Study 2019. Front Med (Lausanne), 2021, 8: 738693.
21.	Pfreundschuh M. Age and sex in non-Hodgkin lymphoma therapy: it's not all created equal, or is it. Am Soc Clin Oncol Educ Book, 2017, 37: 505-511.
22.	Crozier JA, Sher T, Yang D, et al. Persistent disparities among patients with T-cell non-Hodgkin lymphomas and B-cell diffuse large cell lymphomas over 40 years: a SEER database review. Clin Lymphoma Myeloma Leuk, 2015, 15(10): 578-585.
23.	郑湧智, 陈再生, 华雪玲, 等. 儿童不同病理亚型非霍奇金淋巴瘤的临床特征及预后因素. 中国实验血液学杂志, 2020, 28(2): 500-506.
24.	Sandlund JT, Martin MG. Non-Hodgkin lymphoma across the pediatric and adolescent and young adult age spectrum. Hematology Am Soc Hematol Educ Program, 2016, 2016(1): 589-597.
25.	Howlader N, Morton LM, Feuer EJ, et al. Contributions of subtypes of non-Hodgkin lymphoma to mortality trends. Cancer Epidemiol Biomarkers Prev, 2016, 25(1): 174-179.
26.	中国抗癌协会淋巴瘤专业委员会, 中国医师协会肿瘤医师分会, 中国医疗保健国际交流促进会肿瘤内科分会. 中国淋巴瘤治疗指南(2021年版). 中华肿瘤杂志, 2021, 43(7): 707-735.

1. Armitage JO, Gascoyne RD, Lunning MA, et al. Non-Hodgkin lymphoma. Lancet, 2017, 390(10091): 298-310.
2. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990—2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, 2020, 396(10258): 1204-1222.
3. Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl), 2021, 134(7): 783-791.
4. Liu W, Liu J, Song Y, et al. Burden of lymphoma in China, 2006-2016: an analysis of the Global Burden of Disease Study 2016. J Hematol Oncol, 2019, 12(1): 115.
5. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
6. GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990—2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, 2020, 396(10258): 1223-1249.
7. 屈彦, 王天一, 杨津, 等. GBD数据库的数据提取方法与流程. 中国循证心血管医学杂志, 2019, 11(9): 1043-1046.
8. 李茜瑶, 周莹, 黄辉, 等. 疾病负担研究进展. 中国公共卫生, 2018, 34(5): 777-780.
9. 李辉章, 杜灵彬. Joinpoint回归模型在肿瘤流行病学时间趋势分析中的应用. 中华预防医学杂志, 2020, 54(8): 908-912.
10. Chen HS, Zeichner S, Anderson RN, et al. The Joinpoint-jump and Joinpoint-comparability ratio model for trend analysis with applications to coding changes in health statistics. J Off Stat, 2020, 36(1): 49-62.
11. 胡成如, 王丽, 孙茜, 等. 体重指数与恶性淋巴瘤关系病例对照研究的Meta分析. 中国循证医学杂志, 2012, 12(1): 55-60.
12. 't Mannetje A, De Roos AJ, Boffetta P, et al. Occupation and risk of non-Hodgkin lymphoma and its subtypes: a pooled analysis from the InterLymph Consortium. Environ Health Perspect, 2016, 124(4): 396-405.
13. Morton LM, Slager SL, Cerhan JR, et al. Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr, 2014, 2014(48): 130-144.
14. 杜鹏, 李龙. 新时代中国人口老龄化长期趋势预测. 中国人民大学学报, 2021, 35(1): 96-109.
15. 修冰, 刘辉, 李玉兰, 等. CAR-T治疗B细胞淋巴瘤研究新进展. 临床内科杂志, 2022, 39(9): 586-589.
16. Bock AM, Nowakowski GS, Wang Y. Bispecific antibodies for non-Hodgkin lymphoma treatment. Curr Treat Options Oncol, 2022, 23(2): 155-170.
17. Yip W, Fu H, Chen AT, et al. 10 years of health-care reform in China: progress and gaps in Universal Health Coverage. Lancet, 2019, 394(10204): 1192-1204.
18. Yu H. Universal health insurance coverage for 1.3 billion people:what accounts for China's success? Health Policy, 2015, 119(9): 1145-1152.
19. Liu W, Liu J, Song Y, et al. Burden of lymphoma in China, 1990—2019: an analysis of the global burden of diseases, injuries, and risk factors study 2019. Aging (Albany NY), 2022, 14(7): 3175-3190.
20. Cai W, Zeng Q, Zhang X, et al. Trends analysis of non-Hodgkin lymphoma at the national, regional, and global level, 1990—2019: results from the Global Burden of Disease Study 2019. Front Med (Lausanne), 2021, 8: 738693.
21. Pfreundschuh M. Age and sex in non-Hodgkin lymphoma therapy: it's not all created equal, or is it. Am Soc Clin Oncol Educ Book, 2017, 37: 505-511.
22. Crozier JA, Sher T, Yang D, et al. Persistent disparities among patients with T-cell non-Hodgkin lymphomas and B-cell diffuse large cell lymphomas over 40 years: a SEER database review. Clin Lymphoma Myeloma Leuk, 2015, 15(10): 578-585.
23. 郑湧智, 陈再生, 华雪玲, 等. 儿童不同病理亚型非霍奇金淋巴瘤的临床特征及预后因素. 中国实验血液学杂志, 2020, 28(2): 500-506.
24. Sandlund JT, Martin MG. Non-Hodgkin lymphoma across the pediatric and adolescent and young adult age spectrum. Hematology Am Soc Hematol Educ Program, 2016, 2016(1): 589-597.
25. Howlader N, Morton LM, Feuer EJ, et al. Contributions of subtypes of non-Hodgkin lymphoma to mortality trends. Cancer Epidemiol Biomarkers Prev, 2016, 25(1): 174-179.
26. 中国抗癌协会淋巴瘤专业委员会, 中国医师协会肿瘤医师分会, 中国医疗保健国际交流促进会肿瘤内科分会. 中国淋巴瘤治疗指南(2021年版). 中华肿瘤杂志, 2021, 43(7): 707-735.

Chinese Journal of Evidence-Based Medicine

Analysis of the disease burden of non-Hodgkin lymphoma in China from 1990 to 2019

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content